secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0001193125-23-173863
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Pharma licenses vamorolone rights for DMD from Santhera; $75M upfront + $15M investment
--------------------------------------------------------------------------------

- Catalyst pays $75M upfront for exclusive North America license to vamorolone, a DMD drug under FDA review with PDUFA date Oct 26, 2023.
- Catalyst also invests $15M in Santhera at CHF 0.9477 (~$1.08) per share for Phase IV and additional indication development.
- If approved, Catalyst expects to launch vamorolone in U.S. early Q1 2024; Santhera may receive regulatory/sales milestones and royalties.
- Transaction includes right of first negotiation for Europe and Japan if Santhera seeks partnerships; closing expected Q3 2023.
- Vamorolone has FDA Fast Track and Orphan Drug designations; met primary endpoint in Phase 2b VISION-DMD study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523173863/0001193125-23-173863-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523173863/d499888d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-173863

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer